This is a working overview of secretagogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
=== Phytoestrogens === Isoflavones, which are structurally related to 17β-estradiol, are classified as phytoestrogens. A risk assessment by the European Food Safety Authority found no cause for concern when isoflavones are consumed in a normal diet.
=== 8 May === The Verkhovna Rada passed a bill allowing for the voluntary mobilization of convicts into the Ukrainian Armed Forces for a chance at parole. Those convicted of violent crimes, treason, rape, terrorism or drug dealing would be barred from volunteering. The bill requires Zelenskyy's signature to become law. Ukrainian Justice Minister Denys Maliuska subsequently said in an interview that between 10,000 and 20,000 convicts could be recruited if the bill is signed into law. One person was killed by Russian shelling in Kherson Oblast. Russia claimed to have taken the villages of Kyslivka in Kharkiv Oblast, 20 kilometers from Kupiansk, and Novokalynove, ten kilometers north of Avdiivka. The Ukrainian military confirmed that Russian forces had entered Krasnohorivka and were holed up in the town's refractory plant. A spokesman for Ukraine's Khortytsia operational-strategic group said that its units, mainly the 59th Brigade, had blocked the Russians inside the refractory plant and claimed to have killed 30 Russians over the past day. The governor of Kharkiv Oblast, Oleh Syniehubov, reported a large gathering of Russian forces north of the region. A jury-rigged Kh-101 modified with a second high explosive warhead containing steel fragments was shot down over Ukraine. The EU agreed to donate €3 billion in income from frozen Russian assets to Ukraine "for arms purchases and reconstruction".
== Undergraduate Research Program == The College of Science and Technology offers the CST Undergraduate Research Program (URP). Students selected to participate work with a faculty sponsor to perform research in the faculty member's lab. Students may be asked to participate in conferences, author papers or to showcase their research work in the department or at the URP Research Symposium.
Salvinorin A is not scheduled at the federal level in the United States. Its molecular structure is unlike any Schedule I or II drug, so possession or sales is unlikely to be prosecuted under the Federal Analogue Act.
==== United States ==== In the United States, immediate-release injectable nalmefene was approved in 1995, as an antidote for opioid overdose. It was sold under the brand name Revex. The product was discontinued by its manufacturer around 2008. A generic version was approved for medical use in the United States in February 2022. In May 2023, the Food and Drug Administration (FDA) approved a nalmefene hydrochloride nasal spray, under the brand name Opvee, for the emergency treatment of opioid overdose in people aged twelve years of age and older. In August 2024, the FDA approved a nalmefene hydrochloride auto-injector (Zurnai) for the emergency treatment of known or suspected opioid overdose in people aged twelve years of age and older. The FDA granted the application for the nalmefene hydrochloride auto-injector fast track and priority review designations. The FDA granted approval of Zurnai to Purdue Pharma L.P. As of 2012, nalmefene in pill form, used for the treatment of alcohol dependence and other addictive behaviors, is not available in the United States.
Sources: en.wikipedia.org
Pacinian corpuscles are rapidly adapting phasic receptors that detect gross pressure changes and vibrations in the skin. Pacinian corpuscles have a large receptive field on the skin's surface with an especially sensitive center. The corpuscles are especially sensitive to vibrations, which they can sense even centimeters away. Their optimal sensitivity is 250 Hz, and this is the frequency range generated upon fingertips by textures made of features smaller than 1 μm. Pacinian corpuscles respond when the skin is rapidly indented but not when the pressure is steady (due to the capsule). It is thought that they respond to high-velocity changes in joint position. They have also been implicated in detecting the location of touch sensations on handheld tools.
If a cleft palate is present, the repair normally takes place at 9–12 months old. Before surgery, a polysomnography with a palatal plate in place is needed. This may predict the postoperative situation and gives insight on the chance of the presence of sleep apnea (OSAS) after the operation. Hearing loss is treated by bone conduction amplification, speech therapy, and educational intervention to avoid language/speech problems. The bone-anchored hearing aid is an alternative for individuals with ear anomalies. Zygomatic and orbital reconstruction is performed when the cranio-orbitozygomatic bone is completely developed, usually at the age of 5–7 years. In children, an autologous bone graft is mostly used. In combination with this transplantation, lipofilling can be used in the periorbital area to get an optimal result of the reconstruction. Reconstruction of the lower eyelid coloboma includes the use of a myocutaneous flap, which is elevated and in this manner closes the eyelid defect. External ear reconstruction is usually done when the individual is at least eight years old. Sometimes, the external auditory canal or middle ear can also be treated. The optimal age for the maxillomandibular reconstruction is controversial; as of 2004, this classification has been used: Type I (mild) and Type IIa (moderate) 13–16 years Type IIb (moderate to severe malformation) at skeletal maturity Type III (severe) 6–10 years When the teeth are cutting, the teeth should be under supervision of an orthodontist to make sure no abnormalities occur.
The dugite (Pseudonaja affinis) is a highly venomous Australian brown snake species. The venom of this species contains highly potent presynaptic and postsynaptic neurotoxins and procoagulants. The murine LD50 is 0.66 mg/kg SC. The average venom yield per bite is 18 mg (dry weight of milked venom) according to Meier and White (1995). Rate of envenomation is 20–40% and the untreated mortality rate is 10–20% by cardiac arrest, kidney failure, or cerebral hemorrhage.
The Parliament of Trinidad and Tobago is the legislative branch of the government of Trinidad and Tobago. The Parliament is bicameral. It consists of the elected House of Representatives, which has 41 members elected for a five-year term in single-seat constituencies, and the Senate which has 31 members appointed by the president: 16 government senators appointed on the advice of the prime minister, 6 opposition senators appointed on the advice of the leader of the opposition and 9 independent senators appointed by the president to represent other sectors of civil society.
Sources: en.wikipedia.org
== Mechanism of action == Icotrokinra is a targeted oral peptide that selectively binds to and blocks the interleukin 23 receptor (IL-23R), thereby inhibiting IL-23-mediated signaling. The drug demonstrates high affinity for the human IL-23 receptor with a dissociation constant (KD) of 7.1 pM and inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 of 5.6 pM. The IL-23 pathway plays a central role in the inflammatory cascade underlying various autoimmune conditions, particularly those involving Th17 cells. Unlike injectable biologics that target IL-23 or its receptor, icotrokinra offers the convenience of oral administration while maintaining selective receptor binding.
== The "Discipline" == In the novel, avout follow a life path called the Discipline, sometimes referred to as Cartasian Discipline, after Saunt Cartas, the founder of the mathic world. It is a set of rules governing what is (and is not) allowed for avout to know and/or do, and was codified centuries before the time of the story in the Second New Revised Book of Discipline. Chief among these is that the avout are separated from the Sæculum, or outside world. There are different levels of separation. For example, within a concent, there are different terms of residency. There are 1-, 10-, 100-, and 1,000-year orders. Each of these celebrates "Apert", a festival opening the concent to the outside world and allowing the flow of information between them, on an interval determined by that number. For example, a 10-year order would celebrate Apert once every ten years, remaining isolated otherwise. Likewise, a 100-year order would only celebrate Apert every hundred years, and a 1,000-year order once every 1,000 years. It is an essential part of this that at any time an order celebrates Apert, all orders below it also celebrate Apert. For example, a Millenarian (1,000-year) order would celebrate in the year 3000. Because 3000 is also a multiple of 100, 10, and 1, Centenarian, Decenarian, and Unarian orders would also celebrate. Exceptions to this rule include "hierarchs" (those who administer the concent) who are required to confer with the Sæcular Power on decisions of weight.
== Education == Sereti received a M.D. from the University of Athens in 1991. She did research for one year in Gregory Spear's laboratory at Rush University Medical Center. Sereti completed an internship, residency, and chief residency in medicine at Northwestern University.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.